FRα in ovarian cancer
1 EU-approved indication in ovarian cancer needs a FRα result: mirvetuximab soravtansine (2nd line).
Histology
Platinum
Line of therapy
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| FRα-positive1 | ||||
Elahere | FRα-positive | Monotherapy | 2L | High-grade serous only; After 1 to 3 prior systemic treatment regimens; Platinum-resistant |
8 approvals for Ovarian need no biomarker and apply whatever the result. All approvals for Ovarian
See also
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Mirvetuximab soravtansine (Elahere)
ELAHERE as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens (see section 4.2).